

## Forest plots: trying to see the wood and the trees

Steff Lewis, Mike Clarke

Few systematic reviews containing meta-analyses are complete without a forest plot. But what are forest plots, and where did they come from?

### What is a forest plot?

In a typical forest plot, the results of component studies are shown as squares centred on the point estimate of the result of each study. A horizontal line runs through the square to show its confidence interval—usually, but not always, a 95% confidence interval. The overall estimate from the meta-analysis and its confidence interval are put at the bottom, represented as a diamond. The centre of the diamond represents the pooled point estimate, and its horizontal tips represent the confidence interval. Significance is achieved at the set level if the diamond is clear of the line of no effect.

The plot allows readers to see the information from the individual studies that went into the meta-analysis at a glance. It provides a simple visual representation of the amount of variation between the results of the studies, as well as an estimate of the overall result of all the studies together. Forest plots increasingly feature in medical journals, and the growth of the Cochrane Collaboration has seen the publication of thousands in recent years.<sup>1</sup>

### History

The origin of forest plots goes back at least to the 1970s. Freiman et al displayed the results of several studies with horizontal lines showing the confidence interval for each study and a mark to show the point estimate. This study was not a meta-analysis, and the results of the individual studies were therefore not combined into an overall result.<sup>2</sup> In 1982, Lewis and Ellis produced a similar plot but this time for a meta-analysis, and they put the overall effect on the bottom of the plot (fig 1).<sup>3</sup> However, smaller studies, with less precise estimates of effect, had larger confidence intervals and, perversely, were the most noticeable on the plots.

Means of focusing attention on the larger, more precise, studies were sought. Replacement of the mark with a square whose size was proportional to the precision of the estimate may have been first suggested by Stephen Evans at a Royal Statistical Society medical section meeting at the London School of Hygiene and Tropical Medicine in 1983 (S Evans, personal commun-

### Summary points

Forest plots show the information from the individual studies that went into the meta-analysis at a glance

They show the amount of variation between the studies and an estimate of the overall result

Forest plots, in various forms, have been published for about 20 years

During this time, they have been improved, but it is still not easy to draw them in most standard computer packages

Neurosciences Trials Unit, Department of Clinical Neurosciences, University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU  
Steff Lewis  
*medical statistician*

UK Cochrane Centre, NHS Research and Development Programme, Oxford OX2 7LG  
Mike Clarke  
*associate director (research)*

Correspondence to:  
S Lewis  
steff.lewis@ed.ac.uk

BMJ 2001;322:1479–80

nication). He based the idea on modified box plots.<sup>4</sup> Ideas such as radial plots were also proposed.<sup>5,6</sup>

The first meta-analyses to include squares of different sizes to show the positions of the point estimates were probably those produced by the Clinical Trial Service Unit in Oxford in the 1998 overview of the prevention of vascular disease by antiplatelet therapy.<sup>7</sup> The area of each square was proportional to the weight that the individual study contributed to the meta-analysis.




Fig 1 First use of forest plot for meta-analysis of effect of  $\beta$  blockers on mortality<sup>3</sup> (reproduced with permission from Physicians World/Thomson Healthcare, Secaucus, NJ)




Fig 2 Updated version of Lewis and Ellis's original plot (fig 1) showing effect of  $\beta$  blockers on mortality

We have updated the original Lewis and Ellis plot<sup>3</sup> to show how it might look in the modern style (fig 2). We obtained data for most of the component studies from a subsequent paper.<sup>8</sup> In the 1980s, no standard computer packages could easily produce these plots,

and they came from specially produced computer programs. Even now, most standard statistical packages cannot easily produce such a plot.

### Why a forest plot?

The plot was not called a "forest plot" in print for some time, and the origins of this title are obscured by history and myth. At the September 1990 meeting of the breast cancer overview, Richard Peto jokingly mentioned that the plot was named after the breast cancer researcher Pat Forrest, and, at times, the name has been spelt "forrest plot." However, the phrase actually originates from the idea that the typical plot appears as a forest of lines. A contender for the first use of the name "forest plot" in print is a review of nursing interventions for pain that was published in 1996.<sup>9</sup> An abstract at the Cochrane colloquium later that year also used this name.<sup>10</sup> We would welcome suggestions of precedents to these uses or any other versions of this brief history of the plot.

We thank Jon Godwin for preparing figure 2.

Funding: None.

Competing interests: None declared.

- 1 Cochrane Collaboration. *Cochrane Library*. Issue 1. Oxford: Update Software, 2001.
- 2 Freiman JA, Chalmers TC, Smith H, Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial: survey of 71 "negative trials". *N Engl J Med* 1978;299:690-4.
- 3 Lewis JA, Ellis SH. A statistical appraisal of post-infarction beta-blocker trials. *Prim Cardiol* 1982;suppl 1:31-7.
- 4 McGill R, Tukey JW, Larsen WA. Variations of box plots. *Am Stat* 1978;32:12-6.
- 5 DeMets DL. Methods for combining randomized clinical trials: strengths and weaknesses. *Stat Med* 1987;6:341-50.
- 6 Galbraith RL. A note on graphical presentation of estimated odds ratios from several clinical trials. *Stat Med* 1988;7:889-94.
- 7 Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. *BMJ* 1988;296:320-31.
- 8 Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. *Prog Cardiovasc Dis* 1985;27:335-71.
- 9 Sindhu F. Are non-pharmacological nursing interventions for the management of pain effective? A meta-analysis. *J Adv Nurs* 1996;24:1152-9.
- 10 Bijnens L, Collette L, Ivanov A, Hocini Boes G, Sylvester R. Optimal graphical display of the results of meta-analyses of individual patient data. In: *Proceedings of the 4th Cochrane colloquium, Adelaide, Australia, 1996*. Oxford: Cochrane Collaboration, 1996.

(Accepted 20 February 2001)

### A memorable patient A chandelier and a vat of custard

It was a busy Friday night in casualty. We were one senior house officer down and there had been a major accident on a nearby main road. All of us had been looking after seriously injured patients for the preceding couple of hours—not all of them had survived, and emotions were running high. During that time, the backlog of minor injuries had built up to a six hour wait, and tempers were fraying in the waiting room. The nurses were fielding angry patients, often with trivial injuries, and were desperate for one of us to come and help.

I returned to the minor side to start clearing the backlog as soon as possible. I was in a superefficient and slightly short-tempered mood—didn't they realise that we had to deal with far more important things than cut fingers or drunks? I picked the next card out of the box and went to the cubicle.

With barely a glance at the patient I said brusquely, "Well, what's the matter then?" A middle aged man looked back at me and said, in a nonchalant tone, "I was preparing for my usual Friday night sexual activity when the chandelier broke, and I fell into the vat of custard."

It took a second or two for me to realise what he'd said. I looked up at him in disbelief. "Really?" I asked. "No," he said, "but I've been sitting in the waiting room for two hours trying to pluck up the courage to say that."

As a grin broke over my face, I asked what had really happened, and he told me what he had done. As I treated him, I relaxed and chatted to him as a real person, not a patient.

I spent the rest of the shift smiling. It inspired me to think that someone faced with a long wait had thought up something like that, and kept it in his mind, without getting annoyed or impatient. He changed my perspective, brightened up my evening, and reminded me of the fact that people, not patients, were in the waiting room.

I have long since forgotten his name, but I still think about him when I'm having a bad day.

Katherine Whybrew GP registrar, 19 Beaumont Street Surgery, Oxford